Hervé Hoppenot has been serving as the President and Chief Executive Officer of INCYTE CORP since 2014. With a strong background in the pharmaceutical industry, Hoppenot has played a pivotal role in steering the company towards significant growth and innovation. Before joining INCYTE, he held various leadership positions at companies such as Cephalon and Novartis, where he gained extensive experience in drug development and commercialization. His strategic vision and leadership have been instrumental in transforming INCYTE into a leading biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. Under Hoppenot's leadership, INCYTE has achieved several notable milestones. One of the key achievements during his tenure has been the successful development and commercialization of Jakafi, a groundbreaking treatment for myelofibrosis and polycythemia vera. This drug has not only provided significant clinical benefits to patients but has also been a commercial success, contributing to the company's robust financial performance. Additionally, Hoppenot has overseen the expansion of INCYTE's research and development pipeline, which now includes a diverse range of promising therapies targeting various cancers and inflammatory diseases. His commitment to innovation and patient-centric approaches has solidified INCYTE's position as a leader in the biopharmaceutical industry. As the President and CEO, Hervé Hoppenot continues to lead INCYTE with a focus on advancing scientific discovery and improving patient outcomes. His strategic initiatives have included expanding the company's global presence and forging key partnerships to enhance INCYTE's capabilities in drug discovery and development. Hoppenot's leadership style emphasizes collaboration, integrity, and a relentless pursuit of excellence, qualities that have earned him respect within the industry and among his peers. As INCYTE moves forward, Hoppenot remains dedicated to driving the company's mission of developing transformative medicines that address unmet medical needs.